Pharmaceutical cold chain warehouses have the highest solar self-consumption rates of any UK commercial building type — and GDP compliance is the primary design consideration that differentiates pharmaceutical from standard commercial solar installs.
GDP and solar PV — the key compliance areas
GDP (Good Distribution Practice) does not prohibit solar PV. Three compliance areas: (1) Power resilience: solar operates in parallel with mains grid — no cold chain single point of failure. We provide a grid resilience assessment with every pharmaceutical install. (2) Installation methodology: sealed access, HEPA filtration, temperature logging during roof works. (3) System independence: solar monitoring is a separate data system with no cross-dependencies to temperature monitoring.
Why pharmaceutical cold chain has 90-96% self-consumption
A 10,000 pallet WDA facility has 250-400 kW continuous refrigeration load (24/7). Plus HVAC (50-150 kW), serialisation lines (10-40 kW), monitoring infrastructure (5-20 kW). Total baseload: 300-600 kW, absorbing virtually all rooftop PV generation year-round.
IETF eligibility: manufacturer vs distributor
IETF 30-50% applies to pharmaceutical manufacturers with warehouse operations. Does not typically apply to standalone WDA-only distributors. Key distinction: if physical transformation of API or finished product occurs on-site, IETF eligibility is likely. Pure distribution (WDA only): no IETF, but 90-96% self-consumption makes economics strong regardless (4-5 year payback).
Key UK pharmaceutical cold chain locations
GSK Barnard Castle, AstraZeneca Macclesfield, Wockhardt Wrexham — manufacturer warehouse IETF eligible. Movianto, Alloga, Ceva Healthcare — WDA only, AIA economics.
See more
Pharmaceutical warehouse solar guide: /guides/warehouse-solar-pharmaceutical-cold-chain/. Cold storage solar guide: /guides/warehouse-cold-storage-solar/. Contact: /contact/.